Loading chat...
MD SB527
Bill
Status
Introduced
2/4/2026
Primary Sponsor
Kevin Harris
Click for details
AI Summary
- Establishes the Ibogaine Clinical Research Grant Program within the Maryland Department of Health to fund FDA-overseen clinical drug development trials on the use of ibogaine for treating opioid use disorder and other neurological conditions
- Limits grants to up to 3 eligible research institutions per year, which must be located in Maryland, have expertise in neurological diseases and substance use/PTSD/trauma, operate a neurosurgery program with cardiac intensive care capabilities, and provide matching funds at least equal to the grant amount
- Requires the Governor to include a $500,000 appropriation from the Opioid Restitution Fund in the annual budget for each of fiscal years 2028 through 2030, and adds the Program as an authorized use of Opioid Restitution Fund money
- Administered by the Department of Health in consultation with the Department of Veterans and Military Families, with grant recipients required to submit quarterly progress and financial reports, and the Department required to report annually to the General Assembly by September 30 beginning in 2028
- Takes effect October 1, 2026, and automatically sunsets on September 30, 2031, after a 5-year period
Legislative Description
Public Health - Ibogaine Clinical Research Grant Program - Establishment (Veterans Mental Health Innovations Act)
Rules and Regulations
Last Action
Hearing 2/24 at 1:00 p.m.
2/9/2026
Committee Referrals
Finance2/4/2026
Full Bill Text
No bill text available